Dr Capuzzo speaks with ecancer at ESMO 2018 in Munich about results from lung cancer trials reported at the conference.
He reports a confirmed survival benefit in the PACIFIC trial for patients with high and medium PD-L1 expression, and negative results from a second-line study of atezolizumab in small cell lung cancer, as discussed by Dr Jean-Louis Pujol.
Dr Capuzzo also spoke with ecancer about the IMpower130 study of atezolizumab as first-line NSCLC therapy.
ecancer's filming has been kindly supported by MSD through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.